Immunologic and psychosocial status in chronic fatigue syndrome

Basit Öğe Kaydı
dc.contributor.authorNas, K.
dc.contributor.authorCevik, R.
dc.contributor.authorBatum, S.
dc.contributor.authorSarac, A. J.
dc.contributor.authorAcar, S.
dc.contributor.authorKalkanli, S.
dc.date.accessioned2024-04-24T17:37:31Z
dc.date.available2024-04-24T17:37:31Z
dc.date.issued2011
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjective: The aim of the study was to investigate the immunologic functions and psychosocial status in patients with chronic fatigue syndrome (CFS). Methods: Twenty-five patients with CFS diagnosed by the international CFS definition criteria and 20 age- and gender-matched healthy controls were recruited. Depression was assessed by Beck Depression Inventory (BDI) and health status was assessed by Nottingham Health Profile (NHP).Monoclonal antibodies (MAbs) were measured to identify the following NK cell subsets: CD3, CD4, CD8 and CD56 and cytokine measurements were performed for IL2r, IL6 and IL8 in both patients and control subjects. Results:The BDI and NHP scores of CFS group were found to be significantly higher than in the control group. The absolute numbers of CD56 cell were also significantly decreased in the patients with CFS compared with the healthy controls. There were no other significant differences of NK cell activity (CD3, CD4 and CD8) and there were significant differences in IL6 and IL2r levels between patients and controls. There were significant correlations between serum IL-6 level and sleep, social isolation and physical ability NHP subscores, and betweenCD56 NK cell activity and emotional reaction NHP sub score in CFS patients. Conclusion: Significantly higher ratios of psychological and physical disturbances were found in patients with CFS. Decreased CD56 NK cell activity and increased IL2r levels seem to be important immunopathologic changes in CFS. IL-6 and CD 56 NK cell activity may play an important role in sleep, physical, social, and physicological manifestations of CFS (Tab. 3, Fig. 1, Ref. 36). Full Text in free PDF www.bmj.sk.en_US
dc.identifier.endpage212en_US
dc.identifier.issn0006-9248
dc.identifier.issn1336-0345
dc.identifier.issue4en_US
dc.identifier.pmid21585130
dc.identifier.scopus2-s2.0-79953841386
dc.identifier.scopusqualityQ2
dc.identifier.startpage208en_US
dc.identifier.urihttps://hdl.handle.net/11468/20985
dc.identifier.volume112en_US
dc.identifier.wosWOS:000289503300012
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherComenius Univen_US
dc.relation.ispartofBratislava Medical Journal-Bratislavske Lekarske Listy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChronic Fatigue Syndromeen_US
dc.subjectPsychosocial Statusen_US
dc.subjectCd56en_US
dc.subjectCytokinesen_US
dc.titleImmunologic and psychosocial status in chronic fatigue syndromeen_US
dc.titleImmunologic and psychosocial status in chronic fatigue syndrome
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu